Want to see SYBX full AI Analyst Report?
SYBX Stock Chart & Stats
$1.22
$0.02(1.41%)
At close: 4:00 PM EST
$1.22
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.54 - $1.96
Previous CloseN/A
Volume234.00
Average Volume (3M)41.08K
Market Cap
$7.98M
Enterprise Value$4.96
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.56
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,696,641
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces interest burden and financial fragility, preserving optionality to fund clinical programs via equity or partnerships. Over a 2–6 month horizon this lowers immediate insolvency risk and improves flexibility in choosing non-debt financing.
Dramatic Reduction In Cash BurnA sustained structural decline in operating cash outflows indicates stronger cost discipline and program prioritization. Lower burn extends runway, reduces near-term financing needs, and increases the probability the company can advance key trials without immediate dilutive raises.
Platform-focused Clinical-stage PipelineA differentiated platform in engineered microbial therapies is a durable fundamental strength: it creates proprietary technical barriers, multiple program opportunities, and potential for platform leverage across indications, supporting longer-term value if clinical proof points are achieved.
Bears Say
Negligible Recurring RevenueEssentially no revenue leaves the business reliant on external financing rather than operating cash generation. Over months this constrains strategic options, prevents self-funding of development, and means commercialization risk remains untested and high.
Negative Free Cash Flow And Funding DependencePersistently negative free cash flow forces reliance on equity, partnerships, or grants to sustain operations. That dependence elevates dilution and execution risk for multi-year clinical programs and reduces predictability of advancing the pipeline without external capital.
Shrinking Asset And Equity BaseA marked contraction in assets and equity reduces financial cushions against trial setbacks and increases insolvency risk. Lower capitalization and negative returns (ROE ~ -8%) indicate the company is not yet generating economic value, pressuring long-term sustainability.
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.54 and its highest was $1.96 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $7.98M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,696,641 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
0.11% Insiders
0.04% Mutual Funds
0.20% Other Institutional Investors
99.64% Public Companies and
Individual Investors